New dosing strategies for antibacterial agents in the neonate

Seminars in Fetal and Neonatal Medicine

Volumn 10, Issue 2, 2005, Pages 185-194

  De Hoog, Matthijs ^a   Mouton, Johan W ^a,b   Van Den Anker, John N ^a,c,d,e  

^a SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^b CANISIUS WILHELMINA HOSPITAL   (Netherlands)

^c GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^d CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^e Washington Pediat Pharmacol R   (United States)

Author keywords

Antibiotics; Meningitis; Necrotizing enterocolitis; Neonate; Pharmacodynamics; Review

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMOXICILLIN; AMPICILLIN; ANTIINFECTIVE AGENT; BETA LACTAM ANTIBIOTIC; CARBAPENEM DERIVATIVE; CEFOTAXIME; CEFTAZIDIME; CEFTRIAXONE; CEPHALOSPORIN DERIVATIVE; FLUCLOXACILLIN; GENTAMICIN; GLYCOPEPTIDE; IMIPENEM; INDOMETACIN; LINEZOLID; MEROPENEM; NETILMICIN; PENICILLIN DERIVATIVE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TEICOPLANIN; TOBRAMYCIN; VANCOMYCIN;

CONCENTRATION (PARAMETERS); DIARRHEA; DRUG ABSORPTION; DRUG EFFICACY; DRUG SAFETY; GESTATIONAL AGE; HEARING LOSS; HUMAN; KIDNEY DYSFUNCTION; MENINGITIS; NECROTIZING ENTEROCOLITIS; NEPHROTOXICITY; NEWBORN CARE; NEWBORN HYPOXIA; OTOTOXICITY; REVIEW; TOXICITY;

EID: 13444282014     PISSN: 1744165X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.siny.2004.10.004     Document Type: Review

References (77)

1. J.O. Klein, and S. Michael Marcy Bacterial sepsis and meningitis Remington J.S. Klein J.O. Infectious Diseases of the Fetus & Newborn Infant 1995 WB Saunders & company 836
2. B.J. Stoll, T. Gordon, and S.B. Korones Early onset sepsis in very low birth weight neonates: a report from the national institute of child health and human development neonatal research network J Pediatr 129 1996 72 80
3. S.S. Shah, R.A. Ehrenkranz, and P.G. Gallagher Increasing incidence of gram-negative rod bacteremia in a newborn intensive care unit Pediatr Infect Dis J 18 1999 591 595
4. B.J. Stoll, T. Gordon, and S.B. Korones Late-onset sepsis in very low birth weight neonates: a report from the National Institute of Child Health and Human Development Neonatal Research Network J Pediatr 129 1996 63 71
5. V. Fanos, and A. Dall'Agnola Antibiotics in neonatal infections: a review Drugs 58 1999 405 427
6. A. MacGowan, and K. Bowker Developments in PK/PD: optimising efficacy and prevention of resistance. A critical review of PK/PD in in vitro models Int J Antimicrob Agents 19 2002 291 298
7. A. Drukker, and J.P. Guignard Renal aspects of the term and preterm infant: a selective update Curr Opin Pediatr 14 2002 175 182
8. J.N. van den Anker, W.C. Hop, R.C. Schoemaker, B.J. van der Heijden, H.J. Neijens, and R. de Groot Ceftazidime pharmacokinetics in preterm infants: effect of postnatal age and postnatal exposure to indomethacin Br J Clin Pharmacol 40 1995 439 443
9. M. de Hoog, J.N. van den Anker, and J.W. Mouton Vancomycin: pharmacokinetics and administration regimens in neonates Clin Pharmacokinet 43 2004 417 440
10. M. de Hoog, J.W. Mouton, and J.N. van den Anker The use of aminoglycosides in newborn infants Choonara I. Nunn A.J. Kearns G. Introduction to Paediatric and Perinatal Drug Therapy 2003 Nottingham University Press Nottingham 117 140
11. H. Yoshioka, M. Takimoto, and H.D. Riley Jr. Pharmacokinetics of ampicillin in the newborn infant J Infect Dis 129 1974 461 464
12. M.R. Adrianzen Vargas, M.H. Danton, and S.M. Javaid Pharmacokinetics of intravenous flucloxacillin and amoxicillin in neonatal and infant cardiopulmonary bypass surgery Eur J Cardiothorac Surg 25 2004 256 260
13. J.J. Huisman-de Boer, J.N. van den Anker, M. Vogel, W.H. Goessens, R.C. Schoemaker, and R. de Groot Amoxicillin pharmacokinetics in preterm infants with gestational ages of less than 32 weeks Antimicrob Agents Chemother 39 1995 431 434
14. L.B. Dahl, K. Melby, T.J. Gutteberg, and G. Storvold Serum levels of ampicillin and gentamycin in neonates of varying gestational age Eur J Pediatr 145 1986 218 221
15. B.G. Charles, Y. Preechagoon, T.C. Lee, P.A. Steer, V.J. Flenady, and N. Debuse Population pharmacokinetics of intravenous amoxicillin in very low birth weight infants J Pharm Sci 86 1997 1288 1292
16. L. Herngren Flucloxacillin kinetics in newborn infants Eur J Clin Pharmacol 36 1989 325
17. I. Tessin, B. Trollfors, K. Thiringer, and P. Larsson Ampicillin-aminoglycoside combinations as initial treatment for neonatal septicaemia or meningitis. A retrospective evaluation of 12 years' experience Acta Paediatr Scand 80 1991 911 916
18. L. Herngren, M. Ehrnebo, and U. Broberger Pharmacokinetics of free and total flucloxacillin in newborn infants Eur J Clin Pharmacol 32 1987 403 409
19. T.E. Young, and B. Mangum Neofax: A Manual for Drugs used in Neonatal Care 2003 Acorn Publishing Raleigh, NC
20. G.L. Kearns, R.F. Jacobs, B.R. Thomas, T.L. Darville, and J.M. Trang Cefotaxime and desacetylcefotaxime pharmacokinetics in very low birth weight neonates J Pediatr 114 1989 461 467
21. E. Martin, J.R. Koup, U. Paravicini, and K. Stoeckel Pharmacokinetics of ceftriaxone in neonates and infants with meningitis J Pediatr 105 1984 475 481
22. Y. Aujard, F. Brion, and E. Jacqz-Aigrain Pharmacokinetics of cefotaxime and desacetylcefotaxime in the newborn Diagn Microbiol Infect Dis 12 1989 87 91
23. D.A. Kafetzis, D.C. Brater, A.N. Kapiki, C.V. Papas, H. Dellagrammaticas, and C.J. Papadatos Treatment of severe neonatal infections with cefotaxime. Efficacy and pharmacokinetics J Pediatr 100 1982 483 489
24. J.N. van den Anker, R.C. Schoemaker, and W.C. Hop Ceftazidime pharmacokinetics in preterm infants: effects of renal function and gestational age Clin Pharmacol Ther 58 1995 650 659
25. G.L. Kearns, R.A. Young, and R.F. Jacobs Cefotaxime dosage in infants and children. Pharmacokinetic and clinical rationale for an extended dosage interval Clin Pharmacokinet 22 1992 284 297
26. H.D. Dellagrammaticas, C. Christodoulou, E. Megaloyanni, M. Papadimitriou, J. Kapetanakis, and G. Kourakis Treatment of gram-negative bacterial meningitis in term neonates with third generation cephalosporins plus amikacin Biol Neonate 77 2000 139 146
27. J. de Louvois, R. Dagan, and I. Tessin A comparison of ceftazidime and aminoglycoside based regimens as empirical treatment in 1316 cases of suspected sepsis in the newborn. European Society for Paediatric Infectious Diseases-Neonatal Sepsis Study Group Eur J Pediatr 151 1992 876 884
28. J.N. van den Anker, R.C. Schoemaker, B.J. van der Heijden, H.M. Broerse, H.J. Neijens, and R. de Groot Once-daily versus twice-daily administration of ceftazidime in the preterm infant Antimicrob Agents Chemother 39 1995 2048 2050
29. I. Tessin, K. Thiringer, B. Trollfors, and J.E. Brorson Comparison of serum concentrations of ceftazidime and tobramycin in newborn infants Eur J Pediatr 147 1988 405 407
30. S. Fink, W. Karp, and A. Robertson Ceftriaxone effect on bilirubin-albumin binding Pediatrics 80 1987 873 875
31. J.A. Hoffman, E.O. Mason, and G.E. Schutze Streptococcus pneumoniae infections in the neonate Pediatrics 112 2003 1095 1102
32. C.M. Paap, and M.C. Nahata Clinical pharmacokinetics of antibacterial drugs in neonates Clin Pharmacokinet 19 1990 280 318
33. Anonymous Early neonatal drug utilization in preterm newborns in neonatal intensive care units. Italian Collaborative Group on Preterm Delivery Dev Pharmacol Ther 11 1988 1 7
34. M. de Hoog, J.W. Mouton, R.C. Schoemaker, C.M. Verduin, and J.N. van den Anker Extended-interval dosing of tobramycin in neonates: implications for therapeutic drug monitoring Clin Pharmacol Ther 71 2002 349 358
35. M. de Hoog, B.A. van Zanten, W.C. Hop, E. Overbosch, N. Weisglas-Kuperus, and J.N. van den Anker Newborn hearing screening: tobramycin and vancomycin are not risk factors for hearing loss J Pediatr 142 2003 41 46
36. C. Meyer, J. Witte, and A. Hildmann Neonatal screening for hearing disorders in infants at risk: incidence, risk factors, and follow-up Pediatrics 104 1999 900 904
37. R.D. Moore, P.S. Lietman, and C.R. Smith Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration J Infect Dis 155 1987 93 99
38. W. Semchuk, J. Borgmann, and L. Bowman Determination of a gentamicin loading dose in neonates and infants Ther Drug Monit 15 1993 47 51
39. D.P. Nicolau, C.D. Freeman, P.P. Belliveau, C.H. Nightingale, J.W. Ross, and R. Quintiliani Experience with a once-daily aminoglycoside program administered to 2,184 adult patients Antimicrob Agents Chemother 39 1995 650 655
40. J.M. Prins, G.J. Weverling, K. de Blok, R.J. van Ketel, and P. Speelman Validation and nephrotoxicity of a simplified once-daily aminoglycoside dosing schedule and guidelines for monitoring therapy Antimicrob Agents Chemother 40 1996 2494 2499
41. M. de Hoog, R.C. Schoemaker, J.W. Mouton, and J.N. van den Anker Tobramycin population pharmacokinetics in neonates Clin Pharmacol Ther 62 1997 392 399
42. F.S. Lundergan, G.F. Glasscock, E.H. Kim, and R.S. Cohen Once-daily gentamicin dosing in newborn infants Pediatrics 103 1999 1228 1234
43. A. Kotze, P.R. Bartel, and D.K. Sommers Once versus twice daily amikacin in neonates: prospective study on toxicity J Paediatr Child Health 35 1999 283 286
44. J. Kallman, E. Kihlstrom, L. Sjoberg, and J. Schollin Increase of staphylococci in neonatal septicaemia: a fourteen-year study Acta Paediatr 86 1997 533 538
45. A.P. Craft, N.N. Finer, and K.J. Barrington Vancomycin for prophylaxis against sepsis in preterm neonates Cochrane Database Syst Rev 2000 2
46. V. Bhatt-Mehta, R.E. Schumacher, R.G. Faix, M. Leady, and T. Brenner Lack of vancomycin-associated nephrotoxicity in newborn infants: a case- control study Pediatrics 103 1999 e48
47. P.L. Degraeuwe, G.H. Beuman, F.H. van Tiel, W.J. Maertzdorf, and C.E. Blanco Use of teicoplanin in preterm neonates with staphylococcal late-onset neonatal sepsis Biol Neonate 73 1998 287 294
48. M.D. Reed, T.S. Yamashita, C.M. Myers, and J.L. Blumer The pharmacokinetics of teicoplanin in infants and children J Antimicrob Chemother 39 1997 789 796
49. E.J. Begg, M.L. Barclay, and C.J. Kirkpatrick The therapeutic monitoring of antimicrobial agents Br J Clin Pharmacol 47 1999 23 30
50. M. Nagl, C. Neher, J. Hager, B. Pfausler, E. Schmutzhard, and F. Allerberger Bactericidal activity of vancomycin in cerebrospinal fluid Antimicrob Agents Chemother 43 1999 1932 1934
51. U.B. Schaad, J.D. Nelson, and G.H. McCracken Jr. Pharmacology and efficacy of vancomycin for staphylococcal infections in children Rev Infect Dis 3 1981 S282 S288
52. S.H. Naqvi, W.J. Keenan, R.M. Reichley, and K.P. Fortune Vancomycin pharmacokinetics in small, seriously ill infants Am J Dis Child 140 1986 107 110
53. F. Pawlotsky, A. Thomas, M.F. Kergueris, T. Debillon, and J.C. Roze Constant rate infusion of vancomycin in premature neonates: a new dosage schedule Br J Clin Pharmacol 46 1998 163 167
54. A.P. Wilson Clinical pharmacokinetics of teicoplanin Clin Pharmacokinet 39 2000 167 183
55. V. Fanos, N. Kacet, and G. Mosconi A review of teicoplanin in the treatment of serious neonatal infections Eur J Pediatr 156 1997 423 427
56. M. de Hoog, J.W. Mouton, and J.N. van den Anker Why monitor peak vancomycin concentrations? (letter) Lancet 345 1995 646
57. F. Shackley, P. Roberts, P. Heath, I. Bowler, and N. Saunders Trough-only monitoring of serum vancomycin concentrations in neonates J Antimicrob Chemother 41 1998 141 142
58. C. Grimsley, and A.H. Thomson Pharmacokinetics and dose requirements of vancomycin in neonates Arch Dis Child Fetal Neonatal Ed 81 1999 F221 F227
59. A. McDougal, E.W. Ling, and M. Levine Vancomycin pharmacokinetics and dosing in premature neonates Ther Drug Monit 17 1995 319 326
60. A.G. Gous, M.D. Dance, J. Lipman, D.K. Luyt, R. Mathivha, and J. Scribante Changes in vancomycin pharmacokinetics in critically ill infants Anaesth Intensive Care 23 1995 678 682
61. K.A. Rodvold, C.A. Gentry, G.S. Plank, D.M. Kraus, E. Nickel, and J.R. Gross Bayesian forecasting of serum vancomycin concentrations in neonates and infants Ther Drug Monit 17 1995 239 246
62. G.L. Kearns, G.L. Jungbluth, and S.M. Abdel-Rahman Impact of ontogeny on linezolid disposition in neonates and infants Clin Pharmacol Ther 74 2003 413 422
63. G.L. Jungbluth, I.R. Welshman, and N.K. Hopkins Linezolid pharmacokinetics in pediatric patients: an overview Pediatr Infect Dis J 22 2003 S153 S157
64. W.A. Craig Basic pharmacodynamics of antibacterials with clinical applications to the use of beta-lactams, glycopeptides, and linezolid Infect Dis Clin North Am 17 2003 479 501
65. D.L. Paterson, K.M. Hujer, and A.M. Hujer Extended-spectrum beta-lactamases in Klebsiella pneumoniae bloodstream isolates from seven countries: dominance and widespread prevalence of SHV- and CTX-M-type beta-lactamases Antimicrob Agents Chemother 47 2003 3554 3560
66. J.W. Mouton, D.J. Touzw, A.M. Horrevorts, and A.A. Vinks Comparative pharmacokinetics of the carbapenems: clinical implications Clin Pharmacokinet 39 2000 185 201
67. M.D. Reed, R.M. Kliegman, T.S. Yamashita, C.M. Myers, and J.L. Blumer Clinical pharmacology of imipenem and cilastatin in premature infants during the first week of life Antimicrob Agents Chemother 34 1990 1172 1177
68. J.G. van Enk, D.J. Touw, and H.N. Lafeber Pharmacokinetics of meropenem in preterm neonates Ther Drug Monit 23 2001 198 201
69. A. Pong, and J.S. Bradley Bacterial meningitis and the newborn infant Infect Dis Clin North Am 13 1999 711 733 viii
70. I. Lutsar, G.H. McCracken Jr., and I.R. Friedland Antibiotic pharmacodynamics in cerebrospinal fluid Clin Infect Dis 27 1998 1117 1127 quiz 1128-9
71. R.F. Jacobs, and G.L. Kearns Cefotaxime pharmacokinetics and treatment of meningitis in neonates Infection 17 1989 338 342
72. D.R. Andes, and W.A. Craig Pharmacokinetics and pharmacodynamics of antibiotics in meningitis Infect Dis Clin North Am 13 1999 595 618
73. R. Nau, C. Lassek, M. Kinzig-Schippers, A. Thiel, H.W. Prange, and F. Sorgel Disposition and elimination of meropenem in cerebrospinal fluid of hydrocephalic patients with external ventriculostomy Antimicrob Agents Chemother 42 1998 2012 2016
74. R.J. Boyle, N. Curtis, N. Kelly, S.M. Garland, and J.R. Carapetis Clinical implications of inducible beta-lactamase activity in Gram-negative bacteremia in children Pediatr Infect Dis J 21 2002 935 940
75. P. McMaster, P. McIntyre, R. Gilmour, L. Gilbert, A. Kakakios, and C. Mellis The emergence of resistant pneumococcal meningitis-implications for empiric therapy Arch Dis Child 87 2002 207 210
76. J.S. Lee, and R.A. Polin Treatment and prevention of necrotizing enterocolitis Semin Neonatol 8 2003 449 459
77. S.J. Newel Gastrointestinal disorders Rennie J.M. Roberton N.R.C. Textbook of Neonatology 1999 Churchill Livingstone Edinburgh 744 764